Clinical Trial Update: Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates the efficacy, safety, and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia (wAIHA).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Warm Autoimmune Hemolytic Anemia

Drugs mentioned

• Rilzabrutinib (rilzabrutinib)

Snippet

Sponsor: Sanofi | Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA) | Phase 2 | Status: ACTIVE_NOT_RECRUITING